Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
15 March 2023 - 9:50PM
Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an
innovative pharmaceutical company focused on developing and
commercializing treatments for rare diseases, today announced the
acquisition of rare disease product candidate ET-600 from Tulex
Pharmaceuticals. ET-600 is an innovative product candidate under
development for the treatment of an endocrinology condition that is
estimated to impact less than 5,000 pediatric patients in the
United States.
“As a rare disease product that builds on our established
presence in pediatric endocrinology, ET-600 is a perfect strategic
fit for our portfolio,” said Sean Brynjelsen, CEO of Eton
Pharmaceuticals. “We have repeatedly heard from physicians about
their need for this product to effectively and safely treat their
pediatric patients, so we look forward to working to bring this
potential new treatment option to the market.”
Eton expects to submit a New Drug Application (NDA) for the
product to the U.S. Food and Drug Administration in the second
quarter of 2024, which could allow for an approval and launch of
the product in early 2025. If approved, ET-600 is expected to be a
patent-protected, durable product that can generate significant
long-term revenue and profit for the company.
About Eton PharmaceuticalsEton Pharmaceuticals,
Inc. is an innovative pharmaceutical company focused on developing
and commercializing treatments for rare diseases. The Company
currently has three FDA approved products in ALKINDI SPRINKLE®,
Carglumic Acid tablets, and Betaine Anhydrous for Oral Solution,
and four late-stage pipeline candidates under development with
dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector,
ET-400, and ET-600. In addition, the Company receives royalties on
three FDA-approved products and is entitled to receive milestone
payments on other products. For more information, please visit our
website at www.etonpharma.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements associated with the expected ability of Eton to
undertake certain activities and accomplish certain goals and
objectives. These statements include but are not limited to
statements regarding Eton’s business strategy, Eton’s plans to
develop and commercialize its product candidates, the safety and
efficacy of Eton’s product candidates, Eton’s plans and expected
timing with respect to regulatory filings and approvals, and the
size and growth potential of the markets for Eton’s product
candidates. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Eton’s current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. These and other risks
concerning Eton’s development programs and financial position are
described in additional detail in Eton’s filings with the
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Eton undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Nov 2024 to Dec 2024
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Dec 2023 to Dec 2024